Dyadic Logo Current.jpg
Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications
26 mars 2024 08h30 HE | Dyadic International, Inc.
The first trial using a C1 produced monoclonal antibody provides equivalent protection against SARS-CoV-2 in hamster and nonhuman primate models compared to monoclonal antibody produced in CHO. ...
AB Science : De nouv
AB Science : De nouvelles recherches montrent que le masitinib limite les dommages neuronaux dans un modèle de maladie neurodégénérative d’origine neuroimmune
13 mars 2024 07h59 HE | AB Science
COMMUNIQUÉ DE PRESSE DE NOUVELLES RECHERCHES MONTRENT QUE LE MASITINIB LIMITE LES DOMMAGES NEURONAUX DANS UN MODÈLE DE MALADIE NEURODÉGÉNÉRATIVE D'ORIGINE NEUROIMMUNE C'EST LA PREMIÈRE FOIS QUE LE...
AB Science: New rese
AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease
13 mars 2024 07h59 HE | AB Science
PRESS RELEASE NEW RESEARCH SHOWS THAT MASITINIB LIMITS NEURONAL DAMAGE IN A MODEL OF NEUROIMMUNE-DRIVEN NEURODEGENERATIVE DISEASE THIS IS THE FIRST DEMONSTRATION THAT MASITINIB CAN LOWER SERUM...
logo.png
Silo Pharma’s SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis
16 oct. 2023 08h11 HE | Silo Pharma, Inc.
Human tissue study assessed SPU-21’s efficiency, optimization, and binding affinity ENGLEWOOD CLIFFS, NJ, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a...
scilogo.jpg
SciSparc Granted European Patent for its Core Technology
03 oct. 2023 07h33 HE | SciSparc Ltd
The receipt of the patent confirms the innovation and uniqueness of the Company's technologies and strengthens its position as a leader in the cannabis space TEL AVIV, Israel, Oct. 03, 2023 ...
BredisHealthcare_logo_hori.png
Bredis Healthcare Awarded South Korean Government Grant for Advancing Early Diagnosis of Alzheimer's Disease
22 août 2023 02h45 HE | Bredis Healthcare Inc.
Bredis Healthcare secures KRW 1.7 billion grant for advancing Alzheimer’s disease diagnosis from South Korean government’s Deep Tech TIPS programNovel platform has demonstrated detection of...
scilogo.jpg
SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S.
01 août 2023 09h00 HE | SciSparc Ltd
TEL AVIV, Israel, Aug. 01, 2023 (GLOBE NEWSWIRE) -- The new U.S. patent application is for the use of the psychedelic molecule 3-MMC and SciSparc's Palmitoylethanolamide to treat dyskinesia and...
scilogo.jpg
SciSparc Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer Disease Patients with Agitation Trial
02 juin 2023 09h00 HE | SciSparc Ltd
Tel-Aviv, June 02, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the...
AB Science annonce l
AB Science annonce la publication de l’étude clinique pivot de phase 3 avec le masitinib dans la maladie d’Alzheimer dans la revue Alzheimer's Research & Therapy
28 févr. 2023 02h03 HE | AB Science
COMMUNIQUE DE PRESSE PUBLICATION DE L'ETUDE CLINIQUE PIVOT DE PHASE 3 AVEC LE MASITINIB DANS LA MALADIE D'ALZHEIMER DANS LA REVUE ALZHEIMER'S RESEARCH & THERAPY Paris, 28 février 2023, 8h AB...
AB Science announced
AB Science announced the publication of the masitinib pivotal phase 3 clinical trial in Alzheimer’s Disease in the journal Alzheimer's Research & Therapy
28 févr. 2023 02h03 HE | AB Science
PRESS RELEASE PUBLICATION OF THE MASITINIB PIVOTAL PHASE 3 CLINICAL TRIAL IN ALZHEIMER'S DISEASE IN THE JOURNAL ALZHEIMER'S RESEARCH & THERAPY Paris, 28 February, 2023, 8am CET ...